Updated:
Zai Lab
Zai Lab is a biopharmaceutical company based in Pudong, China, established in 2014. It was founded on the premise that China would become a significant hub for...
Zai Lab
Zai Lab is a biopharmaceutical company based in Pudong, China, established in 2014. It was founded on the premise that China would become a significant hub for the pharmaceutical and healthcare industry. The company has secured approximately 910 million dollars in total funding.
General information
Firm type
Private Equity
Year founded
2014
Location
Region
Asia
Country
China
City
Shanghai
Corporate office
Building B, 899 Halei Road, Pudong, Shanghai, 201203, P.R. China
Additional offices
Cambridge, MA, United States · San Francisco, CA, United States · San Diego, CA, United States · Beijing, China · Suzhou, China · Hong Kong · Taipei, Taiwan
Principals
Samantha Du
Founder
Sector focus
Frequently asked questions
Who runs investment decisions at Zai Lab, given it operates as a corporation rather than a fund?
As a publicly traded operating company, Zai Lab allocates capital at the corporate level rather than through a GP-led investment committee. Founder and CEO Dr. Samantha Du, together with the senior management team and board of directors, drives pipeline and partnership decisions. This structure means capital allocation is governed by public-company oversight rather than discretionary LP capital calls.
Does Zai Lab participate in fund commitments or only direct drug development?
Zai Lab does not operate as a fund-of-funds or make LP commitments to external venture firms. The company deploys capital directly into internal R&D programs, global in-licensing deals, clinical trials, and its own manufacturing infrastructure.
What is the status of Zai Lab's DLL3-targeted ADC program?
Zai Lab's zocilurtatug pelitecan is a DLL3-targeted antibody-drug conjugate in clinical development for small cell lung cancer. The company has stated the asset holds best-in-class and first-in-class potential based on preclinical and early clinical data, and it anchors the firm's global pipeline ambitions.
How is Zai Lab's business model different from a traditional biotech VC?
Zai Lab integrates discovery, clinical development, regulatory strategy, manufacturing, and commercialization inside a single corporate entity. It does not raise periodic venture funds or pursue a portfolio-company exit model. Revenue from its eight commercial products in China partially funds the pipeline, a structure closer to established biopharma than a typical VC-backed startup.
Which geographies does Zai Lab actively operate in?
Zai Lab runs operations across the United States, mainland China, Hong Kong, and Taiwan. Its R&D footprint includes U.S. sites in Cambridge, South San Francisco, and San Diego, while manufacturing and commercial hubs are concentrated in Shanghai, Suzhou, and Beijing.
Does Zai Lab manage philanthropic capital or a foundation alongside its corporate activities?
There is no public disclosure of a separate philanthropic foundation or impact-investing vehicle linked to Zai Lab as of the latest available records. The company's capital activity is conducted entirely through the publicly listed corporate entity.
What is Zai Lab's known posture on co-investments alongside external GPs?
Zai Lab does not participate in GP-led co-investment syndicates in the traditional venture-capital sense. Its partnering model involves in-licensing agreements and strategic collaborations with global biopharma companies, where it shares development costs or commercial rights on a per-asset basis rather than through pooled investment vehicles.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: